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INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is the name of a 
group of chronic and slowly progressive respiratory disorders 
characterized by reduced maximal expiratory flow during forced 
expiration1. 
 
 COPD is a common and preventable disease that has great 
implications on global health. It is the fourth leading cause of death world 
over, exceeded only by myocardial infarction, malignancy and stroke2. 
 
 COPD is known to cause airflow limitation, impaired gas exchange 
and it also has effects on the pulmonary circulation. 
 
 Pulmonary haemodynamics in patients with  COPD  depends 
on the stage of the disease. In patients with mild obstruction and without 
severe hypoxemia pulmonary arterial pressure is normal at rest. As air 
flow limitation worsens, along with development of chronic severe 
hypoxemia and hypercapnea the pulmonary artery pressure is increased at 
rest. 
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 Spirometers provide quick assessment of expiratory function that 
corrects with FEV1 & also enable us to differentiate between restrictive, 
obstructive & proximal air way disease 3. 
 
 The combination of Pulse oximetry & spirometry give valuable 
Information about patient's status. 
 
 Long standing COPD disease can lead to   exertional & nocturnal 
hypoxemia. 
  
           Frequent Hypoxic episodes & nocturnal hypoxemia leads to the 
development of secondary polycythemia & its consequences.4 
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AIM OF THE STUDY 
 
  To Study the correlation of clinical features, Pulmonary function 
tests, Pulse oximetry assessment  & Haematocrit  abnormalities in 
chronic obstructive pulmonary disease. 
 
         To assess the severity of chronic obstructive pulmonary disease by 
pulmonary function tests.      
 
         To correlate the development of hypoxia and polycythemia with 
respect to severity and duration of the disease. 
  
 To study about the Influence of smoking habit in the development 
& progression of COPD. 
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Review of Literature 
 
 
REVIEW OF LITERATURE 
 
HISTORICAL ASPECTS 
 
 
Arteams (260 AD) had given many clinical descriptions of 
pulmonary disease of which 'pneumodes' might be the same as chronic 
bronchitis, emphysema or bronchial asthma leading to congestive cardiac 
failure. 
 
 In Europe, Bodham (1808) and Laennec (1827) made the classic 
description of chronic bronchitis & emphysema5. 
 
 Laennec in 1926 described the clinical and pathological 
characteristics of cause heart failure even in otherwise healthy heart. 
 
 In 1934 Kountz and Alexander who were studying emphysema 
stated that "it appears that heart is affected in majority of patients with 
emphysema". 
 
 I.T.T. Higgins in 1959 had studied men between the ages of 25 and 
64 to know the relationship between smoking and respiratory symptoms. 
A clear relationship between smoking and persistent cough and sputum 
production has been found6. 
• 1960 Benjamin Burrows studies 200 patients and found out mild 
chronic dyspnea had developed usually at an FEV1 between 1.5 to 
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2.0 litres, one would expect progression to more disability in about 
10 additional years7. 
• 1963 Christer Larson studies 246 Swedish adults with severe α1 – 
antitrypsin deficiency, primary emphysema was present in 109 
cases. Out of other patients with other types of COPD, few showed 
signs of emphysema.8 
• 1959 The Medical Research Council in its publications used the 
term chronic bronchitis to define expectoration when other causes 
such as bronchiectasis or tuberculosis have been excluded, to 
patients who have coughed up sputum on most days during at least 
for 3 consecutive months in 2 successive years9. 
• 1975, Earliest nocturnal polygraph studies were done 
• 1977, Flick MR et al, did a land mark study is to show that Patients  
with COPD experienced a worsening of hypoxia.10 
• 1964-1973 Boushy and colleagues published a series of papers on 
the subject of prognostic factors in COPD and the prognostic 
values of lung function tests in COPD11,12,13. 
• 1977 Boushy SF et al. described the results of hemodynamic 
changes in 136 patients with COPD including serial studies, 
correlating pulmonary function tests, arterial oxygen pressure, and 
arterial carbon dioxide tension with haemodynamic parameters14. 5 
 
 
• 1983, Catterall TR et al., studied about transient hypoxemia during 
sleep in COPD patients15 
• Long-term oxygen in conjunction with pulmonary rehabilitation, it 
also improves quality of life16 
• 1991, Weitzen blume et.al. analysed the evaluation  of 
physiological  variables in patients with  COPD before & during 
long term oxygen trerpy17. 
• 1991, Swimburn stone TN et al., evaluated the symptomatic benefit 
of  supplemental oxygen in hypoxemic patients with chronic lung  
disease 18 
 
DEFINITIONS 
Chronic obstructive pulmonary disease (COPD) is the name of a 
group of chronic and slowly progressive respiratory disorders, 
characterized by reduced maximal expiratory flow during forced 
exhalation1. Most of the airflow obstructions are fixed. 
 
        The American Thoracic Society (ATS) defines COPD as a disease 
process involving progressive chronic airflow obstruction because of 
chronic bronchitis, emphysema, or both19. 
 COPD comprises emphysema, chronic bronchitis & small air way 
disease, although they most often present in combinations. The definition 
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excludes other causes of chronic airflow obstruction such as cystic 
fibrosis, bronchiolitis obliterans and bronchiectasis. 
 
 Chronic bronchitis is defined as the presence of a chronic 
productive cough on most days, for 3 months, in each of two consecutive 
years in a patient in who other causes of chronic cough has been 
excluded.9 
 
 Emphysema is defined as abnormal permanent enlargement of 
distal air apices, distal to the terminal bronchioles, accompanied by 
destruction of their walls and without obvious fibrosis20. 
 
EPIDEMIOLOGY 
 COPD has a chronic protracted course spanning several years or 
even decades. COPD is responsible for considerable morbidity and 
mortality in the community especially among the senior citizens. It is of 
considerable public health importance as there disorders are to a great 
extent preventable. COPD places an enormous burden on health care 
resources and it is one of the major causes of working days lost per years. 
Exacerbations of the disease are more frequent during winter months. 
Chronic bronchitis and emphysema usually coexist. Those patients with 
predominant chronic bronchitis or mainly emphysema form a minority at 
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either end of the disease spectrum of patients with COPD.  
 
PREVALENCE 
In India COPD is the second most common lung disorder after 
pulmonary tuberculosis21 Overall the prevalence is higher in males due to 
greater prevalence of smoking. The disease is most often seen in middle 
aged or elderly people, it is infrequent before the age of 35 years. It has 
been reported from studies in North India that prevalence of chronic 
bronchitis may be as high as 15 % in subjects above 40 years from rural 
areas. Further the prevalence is more in northern India compared to south 
india22. The regional difference has been attributed to climatic conditions, 
particularly the severe winter in North India. The marked preponderance 
of males in urban India is less striking in case of rural areas in the 
country, this has been attributed to greater prevalence of smoking among 
women in rural areas, and it may also be related to marked indoor air 
pollution cakes, firewood and fossil fuels. 
 
 Bhattacharya et.al. studied chronic bronchitis in rural population 
aged more than 30 years and found prevalence of chronic bronchitis to be 
57/100023. There was male preponderance which was higher with 
increasing age. Smoking had direct male preponderance which was 
higher with increasing age. Smoking had direct relation to prevalence was 
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highest among those whose duration was more than 15 years. They also 
found out that prevalence was higher among Hukka smokers (85/'1000) 
as compared to beedi smokers (31/1000). 
 
 It is estimated that there are 14 million cases of COPD in the 
United States. About 12.5 million with chronic bronchitis and 1.65 
million with emphysema. The male to female ratio ranges from 4-6 % /  
1-4 % with increasing prevalence of smoking among females, prevalence 
of COPD in females also has increased. 
 
 The incidence of COPD has been linked to the prevalence of 
smoking in the population as this is the most important etiological factor. 
In a prospective study involving 40,000 medical practitioners in Britain, it 
was found that the death rate from chronic bronchitis was higher in 
smokers and increased with amount smoked. It was also found that those 
who stopped smoking, the mortality after 10 years were much lower than 
those continued to smoke24. 
 
 
 
AETIOLOGY 
 COPD is characterized by a reduced Forced Expiratory Volume in 
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1 second (FEV1) and an accelerated rate of decline of FEV1. The 
reduction in FEV1 can occur by any of three pathways. 
1. Impaired childhood growth and development, with a lower peak in 
early adulthood and a normal rate of decline with aging eg. Early 
Childhood infection and passive smoke exposure. 
2. Normal   growth   and   development   with   premature   peak   but   
normal subsequent decline eg: asthma and passive smoking. 
3.  Normal growth and development and peak, with accelerated decline 
eg: active smoking and to a lesser extent environmental exposures.        
 
SMOKING 
Cigarette smoking is the most commonly identified correlate with 
chronic bronchitis during life25, 26. Pipe and Cigar smokers have a higher 
mortality and morbidity rates for COPD than nonsmokers 27, but lesser 
than cigarettes smokers. Prevalence of COPD shows a dose response 
relationship with the number of pack-years of tobacco consumed. The 
British Thoracic Society guidelines suggest that most patients with COPD 
have at least 20 pack years smoking history28. An average cigarette 
smoker have high annual rate of decline in FEV1, of about 50ml, which is 
nearly double the average value of 30ml in non smokers. In nonsmokers 
1the decline in FEV1 begins at 30-35 years of age and this may occur 
earlier in smokers.  Stopping cigarette smoking does not produce a 
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substantial improvement in FEV1 the subsequent but rate of decline is 
decreased.30 
 
        Clinically significant COPD develops in 15% of cigarette smokers. 
Age of initiation of smoking, total pack-years, and current smoking status 
predict COPD mortality. People who smoke have a greater annual decline 
in FEV1. Overall, tobacco smoking accounts for as much as 90% of the 
risk.5 
 
Prolonged cigarette smoking impairs respiratory epithelial ciliary 
movement, inhibits function of alveolar macrophages and leads to 
hyperplasia and hypertrophy of mucus secreting glands.  Cigarette smoke 
also inhibits anti-proteases and causes polymorpho  nuclear leukocytes to 
release proteolysis enzymes. Smoking is associated with increased airway 
responsiveness which is associated with more rapid progression in 
patients with COPD. Obstruction of small airway is the earliest 
demonstrable mechanical defect in a smoker. 29 
 
  Secondhand smoke, or environmental tobacco smoke, increases 
the risk of respiratory infections, augments asthma symptoms, and causes 
a measurable reduction in pulmonary function5 
ALPHA 1, ANTITRYPSIN DEFICIENCY 
AAT deficiency is the only known genetic risk factor for 
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developing COPD. 
  
α1 Anti Trypsin (AT) is a polymorphic glycoprotein responsible for 
the majority of anti-protease activity in the serum, whose synthesis is 
governed by a gene on 14q 32 chromosome.   
 
  The most common deficient allele termed ZZ (Cor Pizz Phenotype) 
results from a single amino acid substitution 342Glu→Lys, which causes 
spontaneous polymerization of the polypeptide, markedly impairing its 
release into circulation from the liver. It is commonly seen among people 
from European descent 1:2000 to 1:7000 people, rare in people from 
African and Asian lineage.  
  
α1 AT deficiency accounts for 2% of observed cases of 
emphysema. Patients present with premature development of emphysema 
chronic bronchitis or bronchiectasis. The patient usually presents with 
cough and dyspnea in the fourth decade. Nearly 80% had a family history 
of lung disease with autosomal recessive inheritance. The average decline 
of FEV1 is 100-130ml / yr for smokers and 50 to 80 ml /yr for ex-smokers 
or lifetime non smokers. 
Pathologically panacinar emphysema   predominates and   radio 
graphically changes are most marked in lower lobes. Tobacco smoking is 
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an extremely important cofactor for development of disease in  α1 AT 
deficiency. 
 
These patients are also at increased risk of hepatic cirrhosis. 
 
AIR POLLUTION 
Incidence and mortality rates of both chronic bronchitis and 
emphysema may be higher in industrialized urban areas. Exacerbation of 
bronchitis is clearly related to periods of heavy pollution with sulfur 
dioxide and particulate matter. 
 
In developing countries like India traditional cooking fuels such as 
wood, cow dung cake, etc, along with poorly ventilated houses are 
significant risk factors for chronic bronchitis. 
 
OCCUPATION 
Chronic bronchitis is more prevalent in workers who engage in 
occupation exposing them to either inorganic or organic dusts, or to 
noxious gases. Surveys have found an accelerated decline in lung 
function in such workers eg, workers in plastic plants to exposure to 
Toluene etc. Exposure to cadmium can increase the chance of 
development of emphysema and hence COPD. 
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INFECTIONS 
Frequency of acute respiratory illnesses is higher in patients with 
chronic bronchitis. Epidemiological studies however implicate acute 
respiratory illness as one of the major factors associated with etiology as 
well as the progression of chronic airway obstruction. 
 
GROWTH AND NUTRITION 
Studies have shown that nutrition may affect both the growth and 
decline in ventilator function. There is also some evidence that severe 
viral pneumonia early in life may lead to chronic obstruction, particularly 
in small airways. 
 
PATHOLOGY 
The pathologic changes of COPD involve large and small airways 
and the terminal respiratory unit. 
     
  Small airways are the major sites of airflow limitation. Small 
airways show a variety of lesions narrowing their Lumina, including 
goblet cell hyperplasia, mucosal and   sub mucosal   inflammatory cells,   
edema,   peribronchial fibrosis,   intraluminal mucus plugs and increased 
smooth muscle. 
14 
 
 
 
In large cartilaginous airways chronic bronchitis is associated with 
hypertrophy of sub mucosal mucus producing glands. This Mucous gland 
enlargement is the histological hallmark of chronic bronchitis. 
Quantization of this anatomic change is known as Reid index is based on 
thickness of sub mucosal glands to that of bronchial wall. In patients with 
chronic bronchitis it is 0.44+0.09 otherwise normally 0.52 + 0.084. 
 
Emphysema begins as an increase in the number and sizes of 
alveolar fenestrate and results in eventual destruction of alveolar septae 
and their attachments to terminal and respiratory bronchioles.  
 
Emphysema has 3 morphologic patterns : 
  Centriacinar emphysema is characterized by focal destruction 
limited to the respiratory bronchioles and the central portions of acinus. 
This form of emphysema is associated with cigarette smoking and is most 
severe in the upper lobes. 
 
Panacinar emphysema, involves the entire alveolus distal to the 
terminal bronchiole. The panacinar type is most severe in the lower lung 
zones and generally develops in patients with homozygous alpha1- 
antitrypsin (AAT) deficiency. 
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 Distal acinar emphysema or paraseptal emphysema is the least 
common form and involves distal airway structures, alveolar ducts, and 
sacs. This form of emphysema is localized to fibrous septa or to the 
pleura and leads to formation of bullae. The apical bullae may cause 
pneumothorax. Paraseptal emphysema is not associated with airflow 
obstruction. 
 
PATHOPHYSIOLOGY 
Airflow limitation:   Airflow limitation and increased airway resistance 
may be caused by loss of elastic recoil during passive exhalation due to 
emphysema, by increased collapsibility of small airways through loss of 
radial traction on airways, or to increased resistance due to intrinsic 
narrowing of small airways. 
 
Hyperinflation: The residual volume and the functional residual capacity 
(FRC) are almost higher than normal. In addition prolongation of 
expiration is associated with obstruction which would lead to dynamic 
increase in FRC (dynamic hyperinflation). Dynamic hyperinflation 
contributes additionally to discomfort associated with air flow obstruction 
by flattening the diaphragm fiber length and a perpendicular insertion 
with the lower ribs. 
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Impaired Gas Exchange: Maldistribution of inspired air and blood flow 
is always present. When the mismatching is severe, impairment of gas 
exchange is reflected in the abnormalities of arterial blood gases. Small 
airway narrowing causes a decrease in ventilation of their distal alveolar 
acini. When the alveolar capillaries remain intact, this results in mismatch 
of ventilation and perfusion leading to mild or moderate hypoxemia. 
 
(i) Abnormal blood gas tensions 
Hypoxemia: In COPD there is a negative correlation between oxygen 
saturation of the blood and pulmonary artery pressure 31,32,33,34. 
Hypoxemia is known to be a potent arteriolar constrictor in the 
pulmonary circulation (As the severity of disease progresses in COPD 
there is more arterial desaturation correlating with an increase in 
pulmonary hypertension. Exacerbation of COPD with hypoxemia is 
associated with acute worsening of pulmonary hypertension35. Pulmonary 
artery pressure can also increase acutely during the episodes of 
hypoxemia that occur during rapid eye movement of sleep, and it has 
been suggested that recurrent nocturnal pulmonary hypertension can 
result in pathologic changes in pulmonary vessels and fixed 
hypertension36.  
Hypercapnea: In patients with COPD there is a positive correlation 
between arterial CO2 pressure (PaCO2) and pulmonary artery pressure33, 
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37. The mechanism could be a change in lung mechanics due to 
hyperventilation induced by hypercapnea or the potentiating of hypoxic 
pulmonary vasoconstriction. 
 
NOCTURNAL   HYPOXEMIA 
Along with FEV1, hypoxemia also one of the strong prognostic 
markers for COPD. 
 
Healthy individuals have a mean nocturnal SpO2 of above or equal 
to 96%. Even in them during REM sleep there will be short periods of a 
physiological drop with a SpO2 between 93 and 96 percent38 .               
 
COPD Patients may develop substantial decreases in nocturnal 
PaO2 during all phases of sleep, but particularly REM phase. These 
episodes initially are associated with a rise in pulmonary arterial 
pressures and disturbance in sleep architecture, but they may develop into  
Pulmonary arterial hypertension and cor pulmonale if hypoxemia remains 
untreated. 
                              
Desaturation episodes can be defined by a fall in pulse (SpO2) of 
more than 4%, compared to the baseline Level of SpO2 during stable 
respiration, and immediately preceding the hypoxemic episode. 
 
 
 
Patients with severe COPD and with mild to moderate daytime 
hypoxemia (i.e. PaO2 between 55 and 70 mmHg) have a mean nocturnal 
SpO2 of approximately 90%. Daytime PaO2 is clearly the best predictive 
indication of nocturnalSpO2 if daytime hypoxemia is severe, or PaO2 
below 55 mm Hg; mean nocturnal SpO2 may reach as low levels as 75 to 
80%. 
 
In a community-based study of 884 subjects with a mild 
obstructive airway disease, by Sanders MH, Newman AB et al showed 
that 11.4 % of patients had spO2 below 90 %. Which is remarkably high 
compared to a significantly lower value of 6.3 % of subjects without 
obstructive airway disease39. 
 
Two main mechanisms for sleep hypoxemia include alveolar 
hypoventilation and ventilation-perfusion mismatching.  
 
The deleterious effects of hypoxemia proceed from the effects of 
tissue hypoxia on cell metabolism and organ function. 
 
CONSEQUENCES OF HYPOXEMIA 
Hemodynamic effects in the pulmonary circulation:  
Severe episodes of nocturnal desaturation, leading to alveolar 
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hypoxemia causes vasoconstriction of the small pulmonary arteries and a 
rise in mean pulmonary arterial pressure (mPAP). 40, 42  
 
Arrhythmias: Tachycardia’s and other cardiac dysrhythmias common in 
COPD patients during sleep. VPC’ s are more frequent during severe 
nocturnal desaturation (SpO2 < 80 %) 41 
 
Secondary polycythemia:  chronic hypoxia leads to increased levels of 
erythropoietin which in turn raises the red blood cell count & haematocrit 
values Exercise intolerance.  
 
Acidemia: Hypoxia and acidemia act synergistically to produce 
pulmonary vasoconstriction in patients with CCPD. Thus for a given 
oxygen saturation, the mean Ppa is higher with increasing arterial 
hydrogen ion concentration43. 
 
(ii) Effects of Abnormal pulmonary mechanics : 
Changes in airway resistance may augment pulmonary vascular resistance 
and increase in pulmonary artery pressure, correlating with decrease in 
FEV144, 45, 46. 
POLYCYTHEMIA  
Chronic hypoxia causes stimulation of erythropoietin production 
leading to compensatory erythrocytosis 60. Polycythemia defined as             
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Hb >17 g/dL in men  and >15 g/dL in women. 
 
However Polycythemia is uncommon in COPD various studies 
show that it occurs in 5-8% of cases48,49  cigarette smoking may determine 
the severity of  secondary polycythemia in patients with hypoxic COPD, 
and prevent its correction by long-term oxygen therapy.                                            
 
In a study by Atchison R, Russell N et al showed that commonest 
physiological abnormality in smokers was a raised red cell mass 
combined with a low plasma volume.  
 
Six of the 14 patients in their study showed improvement in their 
haematocrit by reducing their smoking habit. 
  
Another study by Calverley PM, Leggett RJ, et al also stated that 
Smoking as a major cause of polycythaemia50 chronic elevation of 
carboxy haemoglobin to 10 or 15% in smokers can lead to secondary 
polycythemia. 
Symptoms of Secondary Polycythemia include Weakness, Fatigue, 
Headache, Light-headedness, Shortness of breath, Night sweats, 
Gastrointestinal, Paresthesias Pruritus, Visual disturbance59.           
 
 
 
CLINICAL FEATURES29  
Symptoms 
The characteristic symptoms of COPD are breathlessness on 
exertion, mostly accompanied by wheeze and cough, which is often but 
not invariably productive. Most patients have a smoking history of at 
least 20 pack years before symptoms develop, commonly in the fifth 
decade. 
 
Breathlessness is the symptom that causes most disability and is 
associated with loss of lung function over time. It is usually first noticed 
on climbing hills or stairs. The appearance of breathlessness indicates 
moderate to severe impairment of airway function.51 by the time patient 
seeks medical help FEV1 has usually fallen to, 1-1.5 lit in an average 
male. However, when the FEV-1 has fallen to 30% or less of the predicted 
values breathlessness is usually present on minimal exertion.  
 
In most patients with COPD cough precedes the onset of 
breathlessness. Sputum is usually mucoid in character, but becoming 
purulent during exacerbations. Volume is generally small and less than 
60ml per day. As COPD progresses exacerbations becomes more frequent 
and severe. 
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Wheezing is present but is neither specific nor indicates the 
severity of obstruction. 
   
With disease progression, intervals between acute exacerbations 
become shorter; cyanosis and right heart failure may occur. Anorexia and 
weight loss often develop and suggest a worse prognosis9 
 
Physical Signs 
These are not specific to the disease and depend on degree of air 
flow limitation over inflation. In early disease the only abnormal finding 
is wheeze on forced expiration and a forced expiratory time prolonged 
beyond 6 seconds with more advanced disease the breathing pattern is 
characterised with a prolonged expiratory phase. Some patients adopting 
pursed-lip breathing on expiration which may reduce expiratory airway 
collapse. The use of accessory muscles of respiration particularly 
sternomastiod is seen in advanced disease. These patients adopt the 
position of leaning forward, supporting themselves with their arms to fix 
the shoulder girdle and allowing the use of pectoralis and latissimus dorsi 
to increase chest wall movements. (The tripod position). 
In later stages the chest is often barell shaped, an increased anterior 
posterior diameter, horizontal ribs, prominence of the sternal angle and 
wide sub costal angle. An inspiratory tracheal tug may be detected. The 
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horizontal position of diaphragm also acts to pull on the lower ribs during 
inspiration (Hoover's sign).52 
 
On percussion there is decreased cardiac and hepatic dullness, 
indicating over inflation. 
 
Breath sounds may have a prolonged expiratory phase or may be 
uniformly diminished. 
 
 
 
 
 
 
 
 
 
 
 
Table -1 CLINICAL TYPES OF PATIENTS WITH COPD53 
 
Emphysema(Type A) 
Pink Puffer 
Chronic Bronchitis
(Type B) Blue 
24 
 
 
Bloater 
Age in years 55-75 45-65 
Cough Short duration 
(often after dyspnea 
starts) 
Long duration 
(usually before 
dyspnea starts 
Sputum Scanty, mucoid Copious, purulent 
Recurrent infection Mild problem Severe problem 
Chest roentgenogram Normal or 
"emphysema" 
Normal or "dirty 
lung" 
Diffusing capacity Low Variable 
Chronic hypercapnea Unusual Common 
Chronic hypoxemia Mild to moderate Often severe 
Erythrocytosis Unusual Common 
Pulmonary artery 
pressure 
Normal or slightly high Often very high 
Chronic cor pulmonale Unusual Common 
Lung compliance High Normal 
Recoil pressure Low Normal 
 
 
 
 
RADIOLOGY 
Chest X-ray: There are no specific features on plain chest-X-ray for 
chronic bronchitis. The features usually described are for emphysema. 
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Bronchial wall thickening seen as parallel line opacities on plain 
chest X-ray has been described in chronic bronchitis. 
Radiographic signs for emphysema are: 
• Low   flattened   diaphragm   :  The   border   of   the   diaphragm   
in   the midclavicular line is below the seventh rib. 
• Height of patient’s lung being greater than 29.9 cm. 
• In lateral film increase in the Retrosternal airspace.  
• An obtuse costophrenic angle. 
• Reduction in size and number of pulmonary vessels particularly in 
periphery of lung. 
• Rapid tapering vascular shadows accompanied by hyperlucency of 
the lungs  
• Heart shadow is vertical and narrow. 
• Computed tomography: Has greater sensitivity and specificity 
than plain chest X-ray for emphysema but is rarely necessary 
except for diagnosis of bronchiectasis, evaluation of bullous lung 
disease.HRCT scan is highly specific for diagnosing emphysema, 
and the outlined bullae.  
PULMONARY FUNCTION TESTS 
Because of imprecision of clinical findings, objective evaluation of 
presence, severity  and  reversibility  of airflow   obstruction is   essential   
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in   the   diagnostic evaluation of COPD. 
 
Spirometry is the most robust test of airflow limitation in patients 
with COPD.  Spirometer provides a graphic output, which enables 
differentiation between restrictive, obstructive, and proximal airway 
disease. 
 
Forced expiratory volume in one second (FEV1) is recommended 
as the measurement of choice in COPD because, 
• FEV1 is reproducible and objective measurement. 
• It is simple and relatively quick to measure and can be measured at 
all stages of disease. 
• The forced expiratory maneuver records not only FEV1 but also FVC 
and FEV1 / FVC ratio less than 70% is diagnostic of airway 
obstruction 
•  A decline in the FEV1 has the most predictive value.54 
• Serial measurement provides evidence of disease progression. Over 
time by assessing FEV1. FEV1 declines with normal ageing at about 
30 ml/year and this increase to an average of 45 ml/year in smokers55. 
 
 
Table -2 Patterns of Pulmonary Function Abnormality29 
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Normal* 
(%) 
Obstructive Restrictive Combined 
VC > 80 N to decreased decreased decreased 
FEV1 > 80  N to decreased decreased decreased 
FEV1/FVC% > 75 decreased N to 
increased 
decreased 
FEF25-75% > 80 decreased decreased decreased 
TLC 80-120 N to increased decreased Decreased, 
can be  N or  
increased 
RV/TLC% 25-40 increased  increased increased 
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Table-3 CLASSIFICATION OF SEVERITY31 
Stage Characteristic 
0 : At risk • Normal spirometry 
• Chronic symptoms (cough, 
sputum production) 
I. Mid COPD • FEV1 / FVC < 70% 
• FEV1 > 80% predicted 
• With or without chronic 
symptoms 
II. Moderate COPD  • FEV1 / FVC < 70% 
• 50% < FEV1 > 80% predicted 
• With or without chronic 
symptoms 
III. Severe COPD  • FEV1 / FVC < 70% 
• 30% < FEV1 > 50% predicted 
• With or without chronic 
symptoms 
IV. Very Severe COPD  • FEV1 / FVC < 70% 
• FEV1<  30% predicted 
• FEV1 > 50% predicted plus 
respiratory failure. 
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Flow Volume Loops 
Expiratory flow at 75% or 50% of vital capacity have been used as 
a measure of airflow limitation and provide complementary information 
to the usual volume time plot. There are problems with the reproducibility 
of these measurements and hence not preferred for routine clinical use. 
 
Reversibility to bronchodilators 
Reversibility tests are important because  
1.   To help distinguish those patients with marked reversibility (at least 
12% or 200ml of FEV1) who have underlying asthma. 
2. To aid with future management. 
3. The FEV1, after bronchodilator is the best predictor of survival. 
It is usually recommended that the response to bronchodilator be 
assessed either using repeated doses from metered dose inhaler or via the 
nebulised route. 
 
Gas transfer for carbon monoxide 
Gas transfer for carbon monoxide values is below normal in many 
patients with COPD and although there is a relationship between gas 
transfer and microscopic emphysema the severity of emphysema in an 
individual patient cannot be predicted from this. 
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Arterial blood gas analysis 
Measurement of arterial blood gas is essential in patients with 
COPD to confirm the degree of hypoxemia and hypercapnea and in acute 
exacerbation to determine the hydrogen ion concentration. Hypercapnea 
commonly is observed as the FEV1 falls below 1 L/s or 30% of the 
predicted value56. 
 
PULSE OXIMETRY    
Pulse oximeters are invaluable, non-invasive tools for the 
assessment of hypoxemia in patients with COPD. However, due to the 
high proportion of smokers in the COPD population, it could be 
beneficial to check the amount of carbon monoxide with whole blood 
oximeters just before starting the sleep study. 
 
Fussell KM, Ayo DS, et al assessed the need for long-term oxygen 
therapy by ambulatory oximetry monitoring57. 
 
 
Pulse oximetry can determine rapidly whether impairment is mild, 
moderate, or severe. Oximetry is accurate to within 3% to 5% at 
saturations greater than 70%. When oxygen saturation is less that 65% to 
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70%, however, the technique is less reliable. Arterial oxygen saturations 
of less than 92% may be associated with the development of a secondary 
polycythemia58. 
 
                  Oximetry is useful in checking that the selected oxygen flow will 
ensure nighttime SpO2 of over 90%. 
 
Patients with pulmonary hypertension or cor pulmonale with 
normal day time blood gases should be evaluated for nocturnal 
desaturation by overnight oximetry. 
 
Table - 4 Practical aspects related to nocturnal pulse oximetry in 
patients with COPD 
Benefits of pulse oximetry Points to note 
Non invasive and well  
tolerated 
Check carbon monoxide (CO) 
levels to ensure SpO2 accuracy 
with smokers 
Monitoring practically in real-Time Accuracy of devices at low SpO2 
values may be variable 
Can assess the effect of  
oxygen therapy 
Clip sensors may be dislodged 
during  sleep, adhesive sensors may 
provide more secure connections 
Results may suggest patients 
requiring polysomnography 
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Other tests :  
α1 AT level are not routinely needed but should be obtained for 
chronic airflow obstruction in non smokers, as well as COPD patients 
with bronchiectasis, cirrhosis without apparent risks, premature or 
bibasilar emphysema in patients under 50 years with unremitting disease 
and in individuals with family history of AT deficiency.   
 
MANAGEMENT OF COPD 
The goal of management is to improve daily living and the quality of 
life by preventing symptoms and the recurrence of exacerbations by 
preserving optimal lung function. 
 Health Education: It can play a role in improving skills, ability to 
cope with illness.Most appropriate topics are, 
• Smoking cessation 
• Basic information about COPD 
• Self management skills 
• Strategies to help decrease dyspnea. 
 
SMOKING CESSATION  
 
Smoking cessation in patients with early COPD improves lung 
function initially and slows the annual decline of FEV161
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BEHAVIORAL TECHNIQUES  
 A Wide Spectrum of Behavioral Techniques has been used to treat 
cigarette addiction. These include education, individual & group 
education, adversive conditioning, psychotherapy, transcental meditation, 
sensory deprivation, hypnosis and desensitization62 
 
Pharmacologic intervention  
      Nicotine is the ingredient in cigarettes primarily responsible for the 
addiction. Withdrawal from nicotine may cause unpleasant adverse 
effects, including anxiety, irritability, difficulty concentrating, anger, 
fatigue, drowsiness, depression, and sleep disruption. These effects 
usually occur during the first several weeks.  
 
 Nicotine replacement therapies after smoking cessation reduce 
withdrawal symptom. Transdermal nicotine patches are available readily 
for replacement therapy. The use of the antidepressant bupropion is also 
effective for smoking cessation. The most recent drug to receive approval 
for smoking cessation is varenicline. 
 
               Other drugs that can be used include lobeline sulfate, 
amphetamines, mecamylamine, antidepressants, clonidine 63. 
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Pharmacologic therapy  
 This   is   used   to   prevent   and   control   symptoms,   reduce   
frequency   of exacerbations and improve exercise tolerance. 
• Bronchodilators are central to management of COPD. Inhaled 
therapy  is preferred. 
• Choice between β2 agonist, anticholinergic theophylline or 
combination therapy depends on availability and individual response 
in terms of symptom relief and side effects. 
• In addition to its anti-inflammatory effects, theophylline improves 
respiratory muscle function, stimulates the respiratory center, and 
promotes bronchodilation. Adding theophylline to the combination 
of bronchodilators can result in further benefit in stable COPD. 
• Bronchodilators are prescribed or   as needed, or on a regular basis to 
prevent or reduce symptoms depending on singe. 
• Long acting bronchodilators are more effective and convenient. 
• Combining bronchodilators improve efficacy and decrease the risk 
of side effects compared to increasing the dose of a single 
bronchodilator. 
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Glucocorticosteroids 
Inhaled steroids are appropriate for symptomatic COPD patients 
with an FEV1<50% predicted (Stage III & IV).Present guidelines 
recommend a trial of 6 weeks to 3 months with inhaled steroids to 
identify patients who may benefit from long term inhalation steroid 
therapy. Long term treatment with oral steroids is not recommended in 
COPD. However in in acute exacerbation of COPD, use of steroids 
improves symptoms and lung function.64 
 
Phosphodiesterase IV inhibitors  
Cilomilast and roflumilast are systemically available, second 
generation, selective phosphodiesterase 4 inhibitors. They cause a 
reduction of the inflammatory process in patients with COPD. 
 
Antibiotics  
          The goal of antibiotic therapy in COPD is not to eliminate 
organisms but to treat acute exacerbations. 
                      
The first-line treatment choices include amoxicillin, cefaclor, or 
trimethoprim / sulfamethoxazole. Second-line antibiotic regimens are the 
more expensive antibiotics, including azithromycin, clarithromycin, and 
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fluoroquinolones. 
Diet : 
          Inadequate nutritional status associated with low body weight in 
patients with COPD is associated with impaired pulmonary status, 
reduced diaphragmatic mass, lower exercise capacity, and higher 
mortality rates. Nutritional support is an important part of their 
comprehensive care. 
 
SURGICAL CARE  
Bullectomy:  Giant bullae may compress adjacent lung tissue, thereby 
reducing the blood flow and ventilation to the healthy tissue. Removal of 
bullae may result in the expansion of compressed lungs and improved 
function 
 
Patients who are symptomatic and have an FEV1 of less than 50% 
of the predicted value have a better outcome after bullectomy. 
 
Lung volume reduction surgery  
Indications for LVRS include, symptoms secondary to severe 
emphysema, marked hyperinflation, and CT scan evidence of 
heterogeneous emphysema. 
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Lung transplantation    
Lung transplantation is   new therapy for advanced lung disease. 
Patients with COPD are the largest single category of patients who 
undergo the process. 
  
Pulmonary Rehabilitation   
Rehabilitation exercises improve exercise tolerance65. It is a 
multidisciplinary  a team approach,  provided by health care professionals 
who have experience in managing COPD (eg, physician, dietitian, nurse, 
respiratory therapist, exercise physiologist, physical therapist, 
occupational therapist, recreational therapist, cardio respiratory 
technician, pharmacist, psychosocial professionals). 
 
 This emphasizes patient and family education, smoking cessation, 
medical management (eg. oxygen, immunization), respiratory and chest 
physiotherapy, physical therapy with bronchopulmonary hygiene, 
exercise, vocational rehabilitation, and psychosocial support. As a result 
of rehabilitation, improvements occur in the objective measures of quality 
of life, well being, and health status, including a reduction in respiratory 
symptoms and an increase in exercise tolerance and functional                 
activities 81. 
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Home Oxygen Therapy (HOT) 
            Apart from smoking cessation, supplemental oxygen therapy is 
the only measure that has been shown to reduce mortality in patients with  
COPD.69Long-term oxygen therapy in conjunction with pulmonary 
rehabilitation, increase life expectancy & improves quality of life 66, 67 
 
                       Supplemental oxygen should be given to patients who are 
hypoxemic with a Pao2 of 55 mm Hg or less, or an oxygen saturation of 
88 percent or less while sleeping. 
 
Standard long-term oxygen therapy is indicated in patients with a 
Pao2 below 55 mm Hg while at rest and awake, and in patients with 
accompanying polycythemia (haematocrit >55%), pulmonary 
hypertension, right-sided heart failure or hypercapnea (Paco2 above 
45mm Hg). To be effective, long-term oxygen therapy should be applied 
for at least 16 hours out of 24 hours, and the sleep period must be totally 
covered 84. The usual rate of oxygen administration is 1.5 to 3 L/min. 
 
Oxygen therapy also decreases in hospital admissions and length of 
hospital stays for acute exacerbations of COPD 68. 
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Nocturnal oxygen therapy  
Patients with COPD may develop substantial decreases in 
nocturnal PaO2 during all phases of sleep; more in REM phase Nocturnal 
oxygen therapy might be indicated in nearly all patients of COPD to 
combat against nocturnal hypoxia69. 
                                                                              
Two landmark trials, The British Medical Research Counsel (MRC 
study) and the National Heart, Lung, Blood Institutes Nocturnal Oxygen 
Therapy Trial (NOTT), showed that long-term oxygen therapy improves 
survival 2-fold or more in hypoxemic patients with COPD. 
 
Benefits of oxygen therapy include amelioration of cor pulmonale, 
enhanced cardiac function, increased body weight, reversal of 
polycythemia, improved neuropsychiatric function and exercise 
performance, reduced pulmonary hypertension, improved skeletal-muscle 
metabolism70. 
 
Home oxygen therapy can be supplied in the form of compressed 
gas cylinders or oxygen concentrators. Oxygen concentrators are most 
and cost effective.  
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Other pharmacologic treatment 
Vaccines: Influenza vaccines can reduce serious illness and death in 
elderly COPD patients by about 50%. 
Alpha-1 Antitrypsin augmentation therapy: Young patients with 
severe α-1 AT deficiency and established emphysema may be candidates 
for the same. 
Antitussives: Regular use is contraindicated in stable COPD.  
 
PHLEBOTOMY   
Repetitive hemodilution by Phlebotomy causes reduction of blood 
viscosity & there by improve pulmonary hemodynamics71, increase 
oxygen uptake, improve pulmonary gas exchange, improves mental 
alertness, work performance, increase in arterial oxygen partial pressure 
(PaO2)72. They also improve exercise tolerance73, 74 and increases the 
cardiac output.  
 
It also reduces iron levels in the body. Study by Martinez JA, 
Guerra CC et al showed reduction in iron level with phlebotomy75. 
Phlebotomy also used as an adjunctive therapy of acutely decompensated 
cor pulmonale in patients with marked polycythemia76. 
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Study by WEdzicha JA, Rudd RM, Apps MC et al proved that 
Erythrapheresis significantly improved symptoms, mental function, and 
work performance in patients with polycythaemia secondary to hypoxic 
lung disease. The procedure was well tolerated by all patients and no 
complications occurred. The mean packed cell volume decreased from 
0.64 to 0.48 in men and from 0.56 to 0.42 in women, with significant 
decreases in blood viscosity77. 
              
Decrease in oxygen transport capacity, hypovolemia, depletion of 
body iron store are  the main complications of phlebotomy. 
 
Intensive care admission: 
Indications include confusion, lethargy, respiratory muscle fatigue, 
worsening hypoxemia, respiratory acidosis (i.e., pH <7.30), newly 
occurring arrhythmias, Significant co-morbidities, Onset of new physical 
signs (cyanosis, peripheral edema) ,Failure of exacerbation to respond to 
initial medical treatment, Severe background COPD or when a patient 
requires invasive or noninvasive mechanical ventilation. Assisted 
ventilation Patients may be treated with noninvasive mask ventilation or 
translaryngeal intubation and mechanical ventilation. 
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   Hemodynamic instability, difficulty with clearing of secretions, 
and copious secretions are contraindications to noninvasive assisted 
ventilation.  
 
The main goal of assisted positive pressure ventilation in acute 
respiratory failure complicating COPD is to rest the ventilator muscles 
and restore gas exchange. Major risks are ventilator-associated 
pneumonia, barotrauma, and laryngotracheal complications associated 
with intubation. 
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Table – 584 
Stages: 
 
Monitor Recommendations 
Stage 0  
At Risk 
Chronic cough and sputum 
production 
Lung function is normal 
Avoidance of risk factors 
Annual Influenza Vaccine 
Stage 1 
 Mild COPD  
 
FEV1 > 80% 
 FEV1/FVC <70%  
Short Acting Bronchodilator 
when needed 
Stage 2 
Moderate 
COPD  
 
FEV1/FVC <70% 
50%<FEV1 <80% 
predicted 
Short acting Bronchodilators as 
needed add one or more long 
acting bronchodilators, 
Pulmonary Rehabilitation 
Stage 3  
Severe COPD 
 
 
 
FEV1/FVC < 70% 
30%<FEV1<50% predicted
Short and long acting 
bronchodilators, Pulmonary 
Rehabilitation, Inhaled 
Glucocorticosteroids ,if repeated 
exacerbations 
Stage 4  
Very Severe 
COPD  
 
FEV1/FVC < 70% 
FEV1<30% predicted or 
FEV1<50% predicted plus 
respiratory failure,signs of 
right heart failure 
Add long term care oxygen 
therapy  
  
 
  
Patient 
Education/ 
Prevention of 
Complications  
 
 
 Smoking cessation  
Yearly Influenza & 
Pneumococcal Vaccine: 
Increase bronchodilator therapy r 
antibiotic therapy, 
Consider corticosteroids if no 
improvement in symptoms 
Administer O2 as needed 
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Prognosis: 
The predictors of mortality are aging, continued smoking, 
accelerated decline in FEV1,80 moderate-to-severe airflow obstruction, 
poor bronchodilator response82, severe hypoxemia, the presence of 
hypercapnea, development of cor pulmonale, and Overall poor functional 
capacity.78, 83 
   
The American Thoracic Society (ATS) has recommended the 
clinical staging of COPD severity according to lung function. Stage I is 
FEV1 of equal or more than 50% of the predicted value. Stage II is FEV1 
35-49% of the predicted value, and stage III is FEV1 less than 35% of the 
predicted value.  
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Table-6 Factors Influencing Survival in Patients with COPD79 
Risk factor Effect on survival 
Post bronchodilator 
FEV1 
Decreases mortality with increased FEV1, 
decreases mortality with reversible component 
of obstruction 
Rate of FEV1 
decline 
Decreases mortality with slower decline; FEV1 
<1 L generally considered severe disease 
History of atopy Decreases mortality 
Higher diffusion 
capacity 
Decreases mortality 
Pao2 level Decreases mortality with increased level; Pao2 
<55 mm Hg increases mortality 
Age Increases mortality in older patients 
Cigarette smoking Increases mortality with continued use and 
greater consumption 
Hypercapnea (Paco2 
>45 mm Hg) 
Increases mortality 
Right-sided heart 
failure 
Increases mortality 
Malnutrition Increases mortality 
Resting tachycardia Increases mortality 
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Materials and Methods 
 
 
MATERIALS AND METHODS 
 
In the present study 50 cases were selected on the basis of simple 
random sampling method from the medical wards of CMC Hospital, 
 
 
Coimbatore. 
 
Study Period: January 2006 to June 2007. 
 
Inclusion Criteria: Adult males and females admitted in the medical 
wards with symptoms suggestive of airway obstruction of more than 2 
years duration and in whom clinical diagnosis of chronic obstructive 
pulmonary disease was made were included in the study. 
 
All these patients were subjected to clinical examination, chest X-
ray, pulmonary function testing, pulse oximetry and Haematocrit analysis 
 
On spirometry the presence of COPD was diagnosed by post 
bronchodilator values of 
(I)   Forced expiratory volume in first second / Forced vital capacity = 
FEV1/FVC less than 70%. 
(ii)   Forced expiratory volume in first Second (FEV1) less than 80% 
All patients were clinically stable at the time of conducting 
pulmonary function test. 
 
Exclusion criteria: Cases which where excluded form the study were 
patients with primary diagnosis of bronchial asthma, pulmonary 
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tuberculosis, Bronchiectasis, cases of sleep apnea syndromes and patients 
with post infarction failure.  
 
Procedure: A proforma was prepared after applying the above inclusion 
and exclusion criteria, meeting the objectives of study  
 
For the present study 50 patients were selected, 42 males and 8 
females and they were subjected to the following examinations. 
 
1. History and Physical Examination 
In every case a detailed history was elicited and thorough clinical 
examination was done as indicated in the proforma. 
 
2. Radiographic examination 
Chest X-ray postero-anterior view and left lateral view were 
obtained to detect signs chronic bronchitis and emphysema 
 
3. Pulmonary Function Testing (PFT) 
PFT was done on computerized spirometer. Spirometery was 
performed when the patients were clinically stable. 
 
Test was performed with the patient comfortably seated, with 
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clothes loosened. The patient was instructed to take a deep inspiration 
then close the lips around the mouth piece and blows out as hard and fast 
as possible, followed by deep inspiration. 
 
Volume was obtained on the vertical axis of recording paper and 
time on the horizontal axis. The curve which was obtained is referred to 
as forced vital capacity curve.  
 
Forced Vital Capacity (FVC) is the volume of air that can be 
forcibly exhaled (as fast as possible) after a maximal inspiration. It is 
expressed in litres. 
 
Forced expiratory volume in one second (FEV1) 
It is defined as the volume of air expelled in the first second, from 
the start of maximum expiratory effort of the forced vital capacity. It is 
expressed in litres or percentage of predicted value.  
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SPIROMETER 
 
PATIENT UNDERGOING SPIROMETRY TESTING 
 
 
 
 
 
 
 
 
 
 
PULSE OXIMETER 
 
 
 
 
 
 
 
 
 
 
 
Forced expiratory volume in one second as a percentage of forced 
vital capacity (FEV1/FVC) 
It is the percentage of forced vital capacity which is expelled in the 
first one second of maximal expiratory effort. 
  
Pulse oximetry : 
            Oxygen saturation was assessed by using pulse oximeters. (Future 
PO, Silicon Lab) 
 
Haematocrit : 
Haematocrit was assessed by using automated analyzer  
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OBSERVATIONS  
AND RESULTS 
 
 
OBSERVATIONS AND RESULTS 
 
 
 
The data was analysed by using the arithmetic mean, the standard 
deviation, standard error, and the correlation coefficient.  
 
50 cases of COPD were studied; the results are tabulated as follows:   
Table - 7: Age Distribution 
Age in years Male Percentag Female Percentag Total Percentage
41-50 3 7.1 1 12.5 4 8 
51-60 8 19.0 2 25.0 10 20 
61-70 18 42.9 3 37.5 21 42 
71-80 12 28.6 1 12.5 13 26 
81-90 1 2.4 1 12.5 2 4 
Total 42 100 8 100 50 100 
 
From the above table it can be observed that the maximum case 
among males were between 61-70 years of age constituting 42.9% and 
the Minimum number cases were in the age group of 81-90 years being 
2.4%. 
 
Among females, maximum number of cases were in the age group 
of 61-70 years constituting 37.5% and the minimum were in the age 
group of 41-50, 71-80 and 81-90 made up of 12.5% each respectively. 
 
Both sexes put together the maximum cases were in age group of 
61-70 years constituting 42% and minimum in the age group of 81-90                       52 
 
 
years constituting only 4%. 
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Table - 8: Mean Age and Standard Deviation of the cases 
 Mean age in years Standard deviation 
Male 65 9.4 
Female 63.75 10.5 
  P>0.05(NS)
 
Mean age of the male patient was 65 + 9.4 years and that of the 
female in the present study was 63.75 + 10.5 years with P > 0.05 
statistically not significant. 
Table-9: Sex Distribution 
Sex Number of Cases Percentage  
Male 42 84 
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Female 8 16 
Total 50 100 
 
Majority of the patients in the present study were males. The male female 
ratio was 5.25:1. 
 
 PIE DIAGRAM SHOWING SEX DISTRIBUTION OF THE 
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Table-10: Occupations of the patients 
 
Occupation Number of patients Percentage 
Farmers 37 74 
Businessmen 5 10 
Housewives 8 16 
Total 50 100 
 
 
In the present study group majority of the patients were farmers 
accounting to 74%. The remaining were businessmen 10% and                     54 
 
 
housewives 16% respectively. 
 
 
Table-11: Urban and Rural distributions 
 Number of patients Percentage 
Rural 45 90 
Urban 5 10 
Total 50 100 
It is observed from the above table that 90% of the patients in the 
present study were from rural background, only 10% of the patients were 
from the urban locales. 
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Table-12: Duration of illness 
Duration of illness 
in years 
Males Females Total Percentage 
2-5 8 0 8 16 
6-10 19 2 21 42 
11-15 13 6 19 38 
16-20 2 0 2 4 
Total 42 8 50 100 
 
 
Table-13: Mean Duration of illness and 
Standard Deviation according to sex 
 Mean (in years) Standard Deviation
Male 9 4 
Female 11.8 2.2 
 
Majority of people in the present study group belonged to more 
than 5 years duration of illness. The mean duration of illness in males was 
9 + 4 years and in females was 11.8 + 2.2 years respectively with P<0.05 
which was statistically significant. 
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Table-14: Risk factor exposure 
 Males Females Total Percentage
History of smoking 42 0 42 84 
Exposure to smoke 
burnt fuels 
0 8 8 16 
Total 42 8  100 
     
 
 All the male patients were smokers; in female H/o exposure to 
smoke of burnt fuels was present in all case. P<0.05 which is statistically 
significant. 
 
Table-15: Duration of smoking habits 
Pack years No. of patients Percentage 
20-30 3 7.14 
30-40 18 42.85 
40-50 16 38.09 
50-60 5 11.90 
Total 42 100.00 
 
 Most of the patients had more than 20 years and majority were in 
30-50 pack year exposure duration.  
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Table 16. Prevalence of COPD and its smoking association in various 
population    studies from India. 
 Population COPD prevalence (%) 
  Men Women M:F Ration 
Smoker:
Non 
Smoker 
Ratio 
 Wig (1964)   Rural Delhi 3.36 2.54 1.3 2.0 
 Sikand (1966)   Delhi 7.0 4.3 1.6 2.5 
 Viswanathan (1966)   Patna 2.12 1.33 1.6   
 Bhattacharya (1975)   Rural U.P 6.67 4.48 1.6   
 Radha (1977)   New Delhi 8.1 4.6 1.8 1.8 
 Thiruvengadam 
(1977)  
 Madras 1.9 1.2 1.6 10.2 
 Viswanathan (1977)   Delhi Rural 4.7 3.5 1.3 9.6 
   Urban 8.0 4.3 1.9 4.0 
 Charan (1977)   Rural Punjab 2.28 1.63 1.4   
 Malik (1986)  
 N.India 
Rural 
9.4 4.9 1.9 5.5 
   Urban 3.7 1.6 2.3 7.0 
 Jindal (1993)  
 N.India 
Rural 
6.2 3.9 1.6   
   Urban 4.2 1.6 2.6 9.6 
 Ray (1995)   South India 4.08 2.55 1.6 1.6 
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Table-17: Presenting Symptoms 
Symptoms No. of patients 
n=50 
Percentage 
Cough  50 100 
Expectoration 50 100 
Breathlessness  46 92 
Wheezing 40 80 
Fever 10 20 
 
All the patients presented with cough and expectoration. 
Breathlessness and wheezing was present in majority of the patients and 
fever was present among a small percentage (20%) of patients.  
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Vital Statistics:  
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Pulse Rate : 18 patients had tachycardia, 27 had pulse rate 
between 80-100/min and 5 had pulse rate below 
80/min. 
Respiratory : 22 patients had tachypnoea 
 
Table-18: Physical Signs 
Signs Number of patients n=50 Percentage 
Cyanosis 7 14 
Flapping tremor 2 4 
Pursed lip Breathing 6 12 
Intercostals in drawing 6 12 
 
Majority of patients were in the stable state with 10-14% of 
patients showing signs of distress. Two patients showed features 
respiratory failure  
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Table-19: Respiratory signs 
Respiratory Sign Number n=50 Percentage 
Decreased chest movements 33 66 
Decreased breath sounds 36 72 
Crepitations / Rhonchus  44 88 
Muffled heart sounds 36 72 
Push down liver  36 72 
Barrel shaped chest 16 32 
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Table-20: Chest X-ray Findings 
X-ray Findings Number of 
Patients 
Percentage
Chronic Bronchitis 10 20 
Emphysema 12 24 
Chronic Bronchitis with emphysema 16 32 
Normal 12 24 
 
In the present study 76% patients had abnormal chest X-ray. Out of 
which 32% had chronic Bronchitis with emphysema , 22% had chronic 
bronchitis and 16%had emphysema 
 
DIAGRAM  SHOWING  CHEST X – RAY  FINDINGS 
20%
24%
32%
24%
Chronic 
Bronchitis
Emphysema
Chronic 
Bronchitis 
with 
emphysema
Normal
 
 
 
                     62 
 
 
Spirometric values 
Though there are many spirometric values FEV1 and FEV1, / FVC 
are often considered as indices of pulmonary function in chronic 
obstructive pulmonary disease. 
1. FEV1 - reflects the degree of airway obstruction. The mean expected 
FEV1, among the subjects studied was 2.44 + 0.5 Lt, however the 
actual mean FEV1 was 1.11 +0.38 liters. The mean FEV1 % of 
expected value in this study was 44.92 + 14.01%. 
2. FVC - Reflect the change in vital capacity. The mean expected FVC 
was 3.03 + 0.42 lt. The actual mean FVC was 2.01 + 0.60 lt. 
3. The mean FEV1 / FVC - was 54.26 + 10.12% in the present study. 
 
Table-21: Range and mean value of PFT findings 
Test Range Mean Standard deviation
FVC ( It)  1.03-3.76 2.01 0.60 
FEV1 (It) 0.60-1.98 1.11 0.38 
FEV1 % 26-78 44.92 14.01 
FEV1 / FVC% 34-73 54.26 10.12 
 
Maximum number of patients in present study were in stage III 
with 40% of the patients showing severe airflow obstruction with a mean 
FEV1 of 45.34 + 4.6%, 24% of patients had very severe obstruction with 
a mean FEV1 of 28.4 + 1.5% and 36% of patients had moderate 
obstruction of FEV1 66.9 + 6.9%. None of the patients study had mild 
obstruction. 
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Table-22: Table showing patients in 
Different stages as per GOLD staging criteria 
Stage No. Percentage Mean FEV in % with SD 
I – Mild COPD 
FEV1>80%  - - - 
II – Moderate COPD 
FEV1 50-80% 18 36 66.9 + 6.9 
III – Severe FEV1  
30-50% 
20 40 45.34+4.6 
IV-Very Severe 
FEV1< 30% 
12 24 28.4+1.5 
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Pulse oximetry assessment:  
              Serum arterial oxygen saturation values are assessed by pulse 
oximeter in all the patients.  
  
Table -23 Distribution of pulse oximetry values in studied population 
SaO2 % No. of patients Percentage % 
<89 8 16 
89 – 92 22 44 
92 – 95 16 32 
>  95 4 8 
 
       In this study patients with H/O chronic smoking (pack years >45) are 
commonly presented with oxygen saturation of <89%. 
 
PIE DIAGRAM SHOWING DISTRIBUTION OF PULSE 
OXIMETRY VALUES IN STUDIED POPULATION 
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Haemoglobin & Haematocrit values  
                All the patients blood samples were assessed by automated 
analyzer .the values were correlated with severity and duration   of the 
disease. 
 
Table - 24   Showing Distribution of Haemoglobin Values Among 
Studied Population 
Hb (g/dl) Male % Female % Total % 
<10 5 11.9 4 50 9 18 
10 -12 6 14.2 2 25.0 8 16 
12 – 15 21 50 2 25.0 23 46 
15 -17 7 16.6 - - 7 14 
>17 3 7.1 - - 3 6 
Total 42 100 8 100 50 100 
     
Table - 25  Distribution of Haematocrit Values Among Studied 
Population 
Haematocrit (% ) Male % Female % Total % 
<40 13 31 6 75 19 38 
40 – 46 22 52.4 2 25.0 24 48 
46 – 53 4 9.5 - - 4 8 
>53 3 7.1 - - 3 6 
Total 42 100 8 100 50 100 
 
 Among the studied population about   3 patients had the values in 
polycythemic range. 
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BAR DIAGRAM SHOWING  DISTRIBUTION  OF 
HAEMATOCRIT VALUES AMONG STUDIED POPULATION 
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Discussion 
 
          DISCUSSION 
 
 
50 cases of chronic obstructive pulmonary disease were studied. 
Mean age in present study was 64.37 + 9.7 years 
 
Table-26: Showing means age 
Study Mean age Standard deviation 
Trivedi H.S. et al., 59.5 4.92 
Higham M.A. et al., 66.7 8.1 
Migueres M. et al.,  60.0 10.81 
Present Study 64.37 9.7 
 
Table-27 Showing sex distribution 
Study Male % Female % Standard deviation 
Trivedi H.S. et al.,  80 20 2.0 
Migueres et al.,  90 10 6.7 
Present Study 84 16 1.6 
 
 In the present study males accounted for 84% with a male female 
ratio of 5.25: 1. 
 
 In the studies quoted the maximum incidence of COPD was in 
males. 
 
 In the present study majority of people belonged to more than 5 
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years duration of illness. The mean duration of illness in males was 9 + 4 
years and females were 11.8 + 2.2 years. 
 
Table-28: Smoking habits in pack years 
Study Mean (Pack years) Standard deviation 
Migueres M. et al., 49.0 22 
Present Study 39.75 18 
 
In the present study lot of the patients had more than 20 pack years 
and majority of patients were in 30-50 pack year exposure duration. The 
mean pack year was 39.75 + 18 years, reinforcing the fact that at least 20 
pack year’s exposure is necessary for development of COPD. 
 
Presenting symptoms 
In the present study, cough with expectoration was present in all 
the cases and breathlessness was present in 92% of cases, wheezing was 
present in 80%and fever  was present in 20% cases 
 
Physical signs 
In the present study cyanosis was present in 7 cases; pursed lip 
breathing and intercostals in drawing was present in 6 cases each, 
flapping tremor was present in 2 cases.  
Incidence of respiratory signs 
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In the present study majority of patients had chronic bronchitis with 
emphysema and 32% of patients had barrel shaped chest. 
 
Chest X-ray 
In the present study x-ray showed features of emphysema in 12 
cases, features of chronic bronchitis in 10 cases & both emphysematous, 
bronchitis changes in 16 cases 
 
SPIROMETRY 
Table-29 Spirometric study, Distribution of cases 
Stage Hingham M.A. et al., (Percentage) 
Present study 
(Percentage) 
I - - 
II 16.42 36 
III 26.00 40 
IV 57.58 24 
Total 100 100 
 
In the study conducted by Higham M.A. et al   majority of patients 
were in stage IV and constituted about 57.58%, whereas in present study 
majority of patients were in group III. 
 
 
PULSE  OXIMETRY 
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In this  study  majority of patients had oxygen saturation values  in 
the range of 89 -95 %.About 8 patients had hypoxia (<89% 
saturation).after oxygen administration , treatment with bronchodilators  
,and intensive care management  they recovered and maintained  normal  
oxygen  saturation levels .   
 
POLYCYTHEMIA 
           In the study, polycythemia was a feature in 6% of cases. In the 
study by Claudia Cote, MD, Marya Zilberberg, MD et al polycythemia 
was present in 5% of patients. In another study by C. Cote, S. H. Mody         
et al, polycythemia was present in 6% of cases. 
 
Table – 30 Prevalence of polycythemia 
Study Percentage of polycythemia 
Claudia Cote, MD, Maria 
Zilberberg, MD et al 
5 
 S. H. Mody, C. Cote et al 6 
Present study 6 
                 
About 3 patients had   polycythemic range of haematocrit values.  
In these patients phlebotomy was done. Reduction in the haematocrit was 
observed .Symptomatic improvement was also observed in these patients. 
                     71 
 
 
 
 
 
 
 
 
 
 
 
summary   
 
SUMMARY 
 
 
 
50 patients of chronic obstructive pulmonary disease were studied. 
1. Majority of the patients were in the age group of 50-70 years. 
COPD was seen predominantly in male patients and majorities 
were smokers. 
2. In the majority of patients the duration of illness was 6-10 years, 
cough with expectoration was present in all patients. 
3. Diminished chest movement, decreased breath sounds, crepitations,  
rhonchi, muffled heart sounds, and pushed down liver were present 
in majority of patients.  
4. As the number of cigarettes/day and duration increases the severity 
of the disease also increases in the studied population.  
5. In the study ,about 40 % of cases were in stage III disease  
6.        Computerised    spirometry    was found to be   most    sensitive    
investigation    in diagnosing and assessing the severity of the 
disease in all these cases.  
7.  As the severity & duration of the disease increases they are more 
prone to develop hypoxia and polycythemia as a complication. In         
our study 8 patients had hypoxia, as assessed by pulse oximeter 
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Conclusion  
 
CONCLUSION 
 
1. Computerized   spirometry   is   a   very   useful   investigation   in   
the management   of   chronic   obstructive   pulmonary   disease.   
 
 
Forced expiratory volume   in first second   (FEV1) values can be 
used to diagnose as well as to assess the severity of the disease. 
2. Pulse oximetry is a useful tool in diagnosing periods of oxygen 
desaturation.  
3.   Pulse oximetry also useful in monitoring the oxygen therapy during 
management.  
4. Haematocrit analysis is a useful adjunct in assessing the severity of 
the disease.  
5. Polycythemia, even though uncommon in chronic obstructive 
pulmonary disease patients is one of the rare but preventable 
complication with early cessation of smoking & with oxygen 
therapy.  
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proforma  
 
PROFORMA 
 
 
 
‘An analysis of pulmonary function tests, Pulse oximetry and 
Haematocrit abnormalities in chronic obstructive pulmonary disease 
patients’ 
 
I. Name    : 2. Age       :   3. Sex     : M/F 
4.    IP NO.           :                   5. DOA     :           6. DOD: 
7.    Occupation   : 8. Economic Status: 
9. Address         : Poor / Middle / High 
10. Presenting complaints 
a. Cough with or without expectoration 
b. Exertional breathlessness 
c. Wheezing 
d. Chest pain 
e.  Hemoptysis 
f.  Fever 
g. Any other symptoms 
II. History of present illness 
a.  Cough 
 Duration 
 Dry / Productive 
 If productive  i)   colour 
    ii) odor  
 
 
iii) Quantity 
iv) Type – Mucoid / mucopurulent / purulent 
Consistent or continuous 
Diurnal / seasonal / postural variation 
Any triggering factors - smoke, dust, pollen 
Status - Increasing / persistent / decreasing 
b. Breathlessness 
Duration 
Persistent / paroxysmal 
Relation to exertion - present / absent 
Seasonal variation 
Precipitating factors 
Duration of attack 
History of PND, Orthopnoea - present / absent 
c. Wheezing 
Duration 
Precipitating factors  
Duration of attacks  
Relieving factors 
 
d. Chest pain 
 Duration 
 
 
 Onset  - acute / insidious 
Location 
 Nature of pain pleuritic / anginal / other types 
 Radiation  neck / shoulder / arm / abdomen 
Aggravating factors Exertion / cough / any other  
Relieving factors  
Duration  of each attack 
e. Hemoptysis 
 Duration 
 Quantity 
 
Type - frank Hemoptysis / blood stained sputum / blood streaked 
Sputum / rusty sputum Fever Duration 
f. Fever  
 Duration 
 Degree   - Mild/Moderate/High 
 Type    - Continuous/remittent/intermittent/
      evening rise of temperature 
 Associated   - Chills - rigor, seating 
g. Any other symptoms - Details 
12. Past history - Similar complaints / tuberculosis / asthma / 
exanthematous fevers in childhood / allergy / epilepsy / cardiac 
 
 
illness / diabetes mellitus. 
 
12. Personal history 
 Diet : Veg / Non-veg/mixed 
 Sleep : Sound/disturbed 
 Snoring : Present / absent 
 Early morning headache : Present / absent 
 Early morning lethargy : Present / absent 
 
Habits 
a) Tobacco chewing 
b) Tobacco smoking 
 i) Beedi / Cigarettes-Pack years 
Duration 
   Quantity / day 
   Current or ex-smoker 
c) Snuff inhaler 
d) Bowels - regular / constipated / loose stools 
e) Bladder-Frequency day / night 
f) Appetite : 
g) Alcohol - Quantity, duration, type 
h) Occupational exposure - Dust / fumes / smoke / chemicals 
 
 
 
14. Family history 
 Tuberculosis - Present / absent 
 Bronchial asthma - Present / absent 
 Allergy like urticaria - Present / absent 
 Rhinitis / eczema - Present / absent 
 
15. General physical Examination 
a. Comfortable / dysphonic 
b. Built: Well built / moderate built / poorly built 
c. Nourishment: Well / Moderate / poorly nourished 
Height : Weight         : 
Pallor : Present / absent 
Cyanosis : Central / Peripheral / mixed 
Icterus : Present / absent 
Clubbing : Present / absent 
Halitosis : Present / absent 
Oedema : Present / absent 
Lymphacienopathy : Present / absent 
Koilonychias / platynychia : Present / absent 
Any other significant signs :  
 
 
16. Vital parameters 
 Pulse: Rate    Rhythm  Volume  Character 
SP 
 Respiration    Rate    Rhythm type 
 Accessory muscle of respiration Acting / normal 
 Pursed lip breathing    Present / absent 
16. Examination of nose, oral cavity, pharynx, teeth and gums 
17. Systemic system 
Respiratory system 
Inspection 
Shape of the chest       : Normal / barrel shaped / pigeon chest / 
pectus Excavatum / kyphoscoliosis / 
Harrison's sulcus /any other deformity 
Position of the trachea : Central / right / left 
Position of the apical impulse : 
Any other pulsation 
Visible veins over the chest    : Present/absent 
 Chest movement Normal     /     diminished     /     symmetrical      
     / asymmetrical 
Stridor / Wheeze 
 
 
 
 
Palpation:      Position of trachea -   Central right / left 
 Position of apical impulse - 
 Movement of chest wall - Normal / decreased  
   Symmetrical /Asymmetrical 
 Palpable crepitations / Rhonchi 
 Vocal fremitus: Normal / increase / decrease 
 
Areas: 
Chest wall tenderness  
Chest measurements  
AP diameter  Transverse diameter 
Chest circumference  Chest expansion 
Percussion note  Normal / impaired / woody dull / stony dull / 
hyper resonant 
Areas: 
Liver dullness  Normal / obliterated  
Cardiac dullness  Normal / diminished 
Auscultation 
Breath sounds  
Intensity  Normal / diminished / increased / absent 
 
 
 
 
Areas: 
 Quality  Vesicular / bronchial / bronchovesicular 
Areas: 
 Rhonchi  Absent / present  
High pitched / low pitched 
Areas: 
Crepitations:   Present / absent 
    Fine / coarse / leathery 
    Inspiratory / expiratory / post tussive  
Areas: 
Pleural rub    Present / absent 
Areas: 
 Vocal resonance  Normal / increased / decreased / absent 
Areas :    Aegophony / whispering pectiroloquy  
Post tussive suction 
18. Cardiovascular system 
 
19. Abdominal examination 
20. Nervous system 
21. Investigations  
 a) Pulmonary function tests 
b) Complete Haemogram 
 
 
  Hemoglobin 
Red cell  count 
 Differential count P L E M B 
  ESR 
 Haematocrit 
c) Biochemistry  
 Random blood sugar  
 Urea  
 Creatinine 
 d) Urine - Protein / sugar / microscopy  
e) Sputum - Microscopy / grams stain 
        AFB 
         Abnormal cells including malignant  
         Cells Culture / sensitivity 
f) Chest radiograph - Report 
g) Electrocardiogram 
h) Pulse oximetry 
i) Any other investigations 
22. Final diagnosis 
 Treatment: 
 Comments 
 
 
 
 
 
 
 
 
 
 
 
 
 
Master Chart 
 
KEY TO MASTER CHART 
 
 
 
M - Male 
F - Female 
A - Agriculture 
B - Businessman 
HW - House wife 
+ - Present 
- - Absent 
↓ - Decreased 
N - Normal 
B - Bronchitis 
E - Emphysematous 
B+E - Bronchitis with Emphysema 
FEV1 - Forced expiratory volume in first second 
FVC - Forced vital capacity 
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1. 26893 65 M A 12 + + + + + 36 - - - 86 37.6 26 132/70 +  ↓  ↓ + + 
2. 26746 72 M A 14 + + + + + 45 - - - 104 38.0 28 130/80 -  ↓  ↓ + + 
3. 26946 67 M A 8 + + + + - 33 - - - 94 37.2 24 136/84 +  ↓  ↓ + + 
4. 27126 54 M A 5 + + - - - 20 - - - 76 37.6 21 140/82 - N N + + 
5. 27456 62 M A 6 + + + + - 35 - - - 96 37.4 24 136/84 -  ↓  ↓ + + 
6. 27762 57 M A 5 + + + + + 25 - - - 88 37.6 20 120/82 - N  ↓ + + 
7. 28526 71 M B 13 + + + + - 45 - - - 110 38.6 30 140/82 -  ↓  ↓ + + 
8. 28762 53 F Hw 7 + + + - - - - - - 104 38.2 28 124/80 - N N + + 
9. 29486 74 M A 11 + + + + - 38 - - - 79 37.2 20 136/74 +  ↓  ↓ + + 
10. 30761 67 M A 11 + + + + - 45 + - - 87 37.6 22 134/80 +  ↓  ↓ + + 
11. 30426 49 M A 2 + + + - - 25 - - - 90 37.8 24 136/84 - N N - - 
12. 30769 76 M A 10 + + + + + 45 - - - 94 37.4 28 140/84 +  ↓  ↓ - - 
13. 31264 58 M A 6 + + + + - 30 - - - 79 37.0 21 140/86 + N N + - 
14. 31424 64 M A 8 + + + + - 45 - - - 84 37.6 20 132/82 -  ↓  ↓ + - 
15. 31764 46 F Hw 5 + + - - - - + - - 72 37.6 19 124/76 - N  ↓ - - 
16. 32326 57 M A 5 + + + - - 30 - - - 82 38 18 128/82 - N N + - 
17. 32124 72 M A 14 + + + + - 34 - - - 112 38.4 26 140/76 -  ↓  ↓ - - 
18. 34264 63 M B 13 + + + + + 35 - - - 84 37.6 20 136/72 +  ↓  ↓ + + 
19. 34126 57 M A 5 + + + + + 30 - - - 94 37.8 24 126/78 +  ↓  ↓ + + 
20. 35762 56 F Hw 11 + + + + + - - - - 106 38.0 28 130/82 - N N - - 
21. 36414 48 M A 3 + + - - + 25 - - - 78 37.1 22 126/76 - N N + - 
22. 37345 68 M B 13 + + + + - 45 - - - 112 38.4 30 134/72 -  ↓  ↓ + + 
23. 37823 84 F Hw 14 + + + + + - + - - 102 37.8 23 140/894 - N  ↓ + + 
24. 38764 47 M A 4 + + - - + 20 - - - 78 37.6 18 126/74 - N N - - 
25. 45328 79 M A 12 + + + + - 55 - - - 94 37.6 24 136/74 -  ↓  ↓ + + 
 
 
  
Routine Investigation Chest x-ray Spirometry Oxygen saturation  Haematocrit 
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1. 15 5.4 11 B+E - + 2.36 0.66 28 2.98 1.03 64 88% 45% 
2. 13 4.5 12 B + - 2.24 1.09 49 2.84 2.01 54 91% 40% 
3. 11 4.2 04 B+E + + 2.60 1.09 42 3.19 2.27 48 91% 37% 
4. 15 5.1 06 B+E + + 2.54 1.98 78 3.14 2.71 73 96% 46% 
5. 12 4.7 13 B+E + + 2.74 2.10 66 3.36 2.58 76 96% 38% 
6. 14 4.3 14 N - - 2.48 1.83 74 3.09 2.69 72 95% 42% 
7. 8 2.5 08 B + - 2.40 0.69 29 2.98 1.18 68 89% 32% 
8. 11 4.1 15 N - - 2.14 1.07 50 2.68 2.43 44 91% 37% 
9. 14 4.2 12 B+E + + 2.74 1.28 47 3.36 2.78 46 79% 42% 
10. 14 4.1 06 B+E - + 2.12 0.97 46 2.67 1.86 52 89% 42% 
11. 9 3.8 39 N - - 2.54 1.98 78 3.14 2.71 73 94% 33% 
12. 14 4.3 18 B+E + + 2.42 1.21 50 3.02 1.95 62 97% 42% 
13. 14.5 4.3 21 B+E - + 2.36 0.82 35 2.94 1.17 70 88% 43% 
14. 14 4.9 04 B+E - + 2.40 0.75 32 2.98 .50 46 80% 49% 
15. 8 2.9 40 N - - 2.60 1.76 68 3.18 2.75 64 93% 32% 
16. 13 4.3 09 N - - 2.32 1.55 67 2.89 2.54 61 91% 40% 
17. 12 4.2 08 B + - 2.42 0.72 30 3.03 1.75 41 89% 38% 
18. 13 4.8 17 B+E + + 2.10 1.01 48.5 2.64 1.42 71 91% 40% 
19. 11.6 4.0 11 B+E + + 2.64 1.24 47 3.19 2.69 46 90% 39% 
20. 14 4.8 12 N - - 2.32 1.16 50 2.92 2.23 52 90% 42% 
21. 12 4.03 06 N - - 2.48 1.83 74 8.09 2.69 68 90% 38% 
22. 15 4.9 08 B + + 2.10 0.60 29 2.63 1.30 46 81% 45% 
23. 8 2.3 35 B + - 2.60 0.78 30 3.22 1.62 48 94% 32% 
24. 13 4.5 17 N - - 2.36 1.51 64 2.91 2.43 62 94% 40% 
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26. 46421 61 M A 6 + + + + + 30 - - - 96 37.8 28 132/80 +  ↓  ↓ + + 
27. 47126 68 M A 9 + + + + + 45 - + - 84 37.8 20 132/76 -  ↓  ↓ + + 
28. 47742 92 M A 18 + + + + - 55 - - - 88 37.6 20 140/80 -  ↓  ↓ + + 
29. 48216 64 F Hw 12 + + + + - - - - - 92 37.8 24 145/70 - N N + + 
30. 48864 73 M A 12 + + + + + 45 - + - 112 38.7 26 126/72 +  ↓  ↓ + + 
31. 49312 67 M A 7 + + + + - 46 - - - 86 37.8 21 134/72 -  ↓  ↓ + + 
32. 49762 77 M B 16 + + + + - 50 - - - 94 38.0 26 142/80 -  ↓  ↓ + + 
33. 50446 72 F Hw 15 + + + + - - - - - 106 39.0 25 136/72 + N N + + 
34. 50876 65 M A 8 + + + + - 35 - - - 79 37.6 20 126/78 +  ↓  ↓ + + 
35. 51210 54 M A 5 + + + - + 30 - - - 75 37.2 20 120/74 -  ↓  ↓ + + 
36. 52874 64 F B 7 + + + + - 20 - - - 84 37.8 20 176/72 +  ↓  ↓ - - 
37. 52976 61 M Hw 12 + + + + - - - - - 86 37.4 21 126/80 - N N - - 
38. 53216 75 M A 14 + + + + - 55 - + - 92 37.6 24 176/70 -  ↓  ↓ + - 
39. 33614 68 M A 10 + + + + + 45 - - - 98 37.2 24 127/72 -  ↓  ↓ + - 
40. 57364 64 M A 7 + + + + - 35 + - - 104 38.2 26 132/76 -  ↓  ↓ - - 
41. 53942 71 M A 13 + + + + - 48 - - - 82 39.0 22 145/80 -  ↓  ↓ + - 
42. 54314 65 M A 6 + + + + - 40 - - - 89 37.0 22 126/70 +  ↓  ↓ - - 
43. 54411 77 M A 14 + + + + - 50 - + - 96 37.0 28 128/72 -  ↓  ↓ + + 
44. 54424 65 F Hw 12 + + + + - - - - - 94 37.4 26 134/76 - N N + + 
45. 54461 68 M A 9 + + + + + 42 - - - 78 37.2 20 130/82 +  ↓  ↓ - - 
46. 54824 59 M A 5 + + + - - 30 - - - 68 37.4 18 134/86 - N N + - 
47. 54562 67 M A 9 + + + + - 42 - - - 92 37.6 24 136/72 +  ↓  ↓ + + 
48. 54576 71 M A 13 + + + + - 45 + - - 81 37.8 20 140/80 -  ↓  ↓ + + 
49. 54632 58 M A 4 + + + - - 30 - - - 74 37.2 19 120/76 - N N - - 
50. 54647 62 M A 5 + + + + - 25 - + - 92 37.6 26 120/80 -  ↓  ↓ + + 
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25. 14 5.1 16 B+E + + 2.16 O.55 26 2.63 1.12 42 89 42 
26. 13 4.3 50 N - - 2.14 1.24 58 2.60 2.00 62 93 40 
27. 18.2 6.4 14 B+E + + 2.77 O.72 26 3.36 2.38 52 88 56 
28. 15.5 5.4 17 B + - 2.60 0.78 28 2.82 1.24 49 89 47 
29. 9.5 4.01 08 B + - 2.64 0.76 29 3.25 1.26 60 94 33 
30. 11.5 4.5 08 E - + 2.48 1.65 66 3.08 1.92 62 96 37 
31. 14 4.9 16 B+E - + 2.46 1.20 49 3.06 2.22 54 92 42 
32. 15.5 5.1 17 B + - 2.36 O.63 27 2.95 1.28 49 91 46 
33. 11.5 4.2 14 E - + 2.72 1.03 38 3.27 1.47 70 92 38 
34. 14.5 5.1 12 B+E + + 2.64 1.28 38.5 3.17 3.76 34 91 44 
35. 11 4.02 13 N - - 2.15 0.32 15 2.61 0.67 47 92 36 
36. 14.2 4.9 14 B+E + + 2.74 1.05 60 3.36 2.85 71 95 43 
37. 12.4 4.3 12 E - + 2.54 0.76 30 3.08 1.40 54 94 39 
38. 18.5 6.5 11 B + - 2.50 0.67 27 3.03 1.09 61 79 57 
39. 14 4.5 08 E - + 2.36 1.06 45 2.94 2.16 49 94 42 
40. 9 3.9 11 E - + 2.54 0.93 37 3.15 1.78 52 90 33 
41. 14.2 4.8 12 E - + 2.36 1.06 45 2.94 2.16 49 80 43 
42. 15 5.2 14 B+E + + 2.42 1.18 49 3.02 1.90 62 92 45 
43. 18.5 6.6 09 B + - 2.62 0.61 26 2.93 1.29 37 86 57 
44. 9 4.01 42 B + - 2.36 1.14 45 3.13 2.53 45 92 33 
45. 11 4.4 12 B+E + + 2.46 1.47 60 3.06 2.62 56 91 36 
46. 14.5 4.9 13 N - - 2.46 1.42 61 2.96 2.52 56 92 44 
47. 14.5 4.8 14 B+E + + 2.46 1.05 28 3.10 1.51 47 89 44 
48. 8 3.8 15 B+E + + 2.54 0.71 28 3.10 1.51 47 90 32 
49. 14 4.9 16 N - - 2.66 1.91 72 3.19 2.80 68 92 42 
50. 15.5 5.2 26 B+E   + + 2.22 0.87 39.2 2.79 1.72 66.5 90 47 
 
